Journal article
A neuroimaging biomarker for striatal dysfunction in schizophrenia
A Li, A Zalesky, W Yue, O Howes, H Yan, Y Liu, L Fan, KJ Whitaker, K Xu, G Rao, J Li, S Liu, M Wang, Y Sun, M Song, P Li, J Chen, Y Chen, H Wang, W Liu Show all
Nature Medicine | NATURE RESEARCH | Published : 2020
Abstract
Mounting evidence suggests that function and connectivity of the striatum is disrupted in schizophrenia1–5. We have developed a new hypothesis-driven neuroimaging biomarker for schizophrenia identification, prognosis and subtyping based on functional striatal abnormalities (FSA). FSA scores provide a personalized index of striatal dysfunction, ranging from normal to highly pathological. Using inter-site cross-validation on functional magnetic resonance images acquired from seven independent scanners (n = 1,100), FSA distinguished individuals with schizophrenia from healthy controls with an accuracy exceeding 80% (sensitivity, 79.3%; specificity, 81.5%). In two longitudinal cohorts, inter-ind..
View full abstractGrants
Awarded by National Natural Science Foundation of China
Funding Acknowledgements
We thank C. Y. Wang, T. M. Si, G. L. Gong and M. Li for their critical discussions and comments, N. N. Tian for her assistance with figure drawing, and R. E. Perozzi and E. F. Perozzi for reviewing the English and content of this study. This work was supported by the National Key Basic Research and Development Program (973) (grant 2011CB707800 to T.J.), the National Key Research and Development Plan (grant 2016YFC0904300 to B.L.), the Strategic Priority Research Program of Chinese Academy of Science (grant XDB32020200 to B.L.) and the Natural Science Foundation of China (grant 81771451 to B.L.).